Form 4: C4 Therapeutics Director Steven Hoerter Granted 35,500 Stock Options

C4 Therapeutics, Inc. Director Steven L. Hoerter was granted 35,500 stock options with an exercise price of $1.44 per share, as disclosed in a recent SEC Form 4 filing.

Summary

• Steven L. Hoerter, a Director of C4 Therapeutics, Inc. (CCCC), was granted 35,500 stock options.
• The stock options have an exercise price of $1.44 per share.
• The grant date for these options was June 18, 2025.
• The options will vest and become exercisable upon the earlier of June 18, 2026, or the date of the next annual meeting of the Issuer's stockholders, contingent on Mr. Hoerter's continued service on the Board.
• The expiration date for these stock options is June 17, 2035.
• Following this transaction, Steven L. Hoerter beneficially owns 35,500 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The filing reports a routine grant of stock options to a director, which is a standard compensation practice and generally viewed as a neutral to slightly positive event as it aligns management interests with shareholders.

Positives

• The grant of stock options aligns the financial interests of Director Steven L. Hoerter with the long-term performance and shareholder value creation of C4 Therapeutics, Inc.
• Equity compensation is a standard practice for incentivizing directors and retaining talent within public companies.

Future Outlook

The granted stock options are subject to a vesting schedule, becoming exercisable upon the earlier of June 18, 2026, or the next annual meeting of stockholders, provided the director continues their service on the Board.

Industry Context

The grant of stock options to a director is a common form of executive and board compensation in the biotechnology and pharmaceutical industries. This practice aims to align the interests of company leadership with those of shareholders by tying compensation to the company's stock performance.

Comparison to Industry Standards

• Equity compensation, such as stock option grants, is a widely adopted practice across industries, particularly in growth-oriented sectors like biotechnology, to incentivize long-term commitment and performance from directors and executives.
• While specific comparable companies or projects are not detailed in this filing, the structure of this grant (number of options, exercise price relative to current stock value, and vesting schedule) is consistent with typical compensation packages for non-employee directors in publicly traded biotech firms, designed to align their interests with shareholder value creation.

Stakeholder Impact

• Shareholders: The grant of stock options aligns the director's financial interests with the long-term performance of the company's stock, potentially encouraging decisions that enhance shareholder value.

Next Steps

• The stock options will vest and become exercisable upon the earlier of June 18, 2026, or the next annual meeting of the Issuer's stockholders, subject to continued service.

Key Dates

Keywords

C4 Therapeutics, CCCC, Stock Option Grant, Director Compensation, Insider Transaction, SEC Form 4, Equity Compensation, Biotechnology